RayKnowChina Research Map
Shortlist0

ChangchunJilin University

First Hospital of Jilin University

吉林大学第一医院

Listed for 37 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at First Hospital of Jilin University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌5 papers led
  3. Hepatocellular carcinoma肝细胞癌76 papers led1 open trial led
  4. Stomach cancer胃癌41 papers led7 open trials led
  5. Hepatoblastoma肝母细胞瘤1 paper led
  6. Retinoblastoma视网膜母细胞瘤3 papers led
  7. Chordoma脊索瘤0 papers led
  8. Osteosarcoma骨肉瘤17 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  10. Neuroblastoma神经母细胞瘤7 papers led
  11. Ewing sarcoma尤文肉瘤2 papers led
  12. Multiple myeloma多发性骨髓瘤17 papers led4 open trials led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  14. Aplastic anaemia再生障碍性贫血2 papers led
  15. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症4 papers led
  16. Haemophilia A血友病 A0 papers led
  17. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征2 papers led
  18. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  19. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病11 papers led
  20. Myasthenia gravis重症肌无力1 paper led
  21. Moyamoya disease烟雾病4 papers led
  22. Wilson disease肝豆状核变性(Wilson 病)2 papers led
  23. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎5 papers led
  24. Takayasu arteritis大动脉炎2 papers led
  25. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  26. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  27. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  28. Fabry disease法布雷病1 paper led
  29. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  30. Behçet disease白塞病3 papers led
  31. Alport syndromeAlport 综合征0 papers led
  32. IgA nephropathyIgA 肾病7 papers led1 open trial led
  33. Gaucher disease戈谢病1 paper led
  34. Osteogenesis imperfecta成骨不全症0 papers led
  35. Primary biliary cholangitis原发性胆汁性胆管炎11 papers led
  36. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  37. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Beta thalassaemia, Fanconi anaemia, IgG4-related disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Pompe disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

2 hospitals in Changchun for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIRadiotherapy techniqueSide effects & quality of life
Departments in papersRadiation oncology
Papers it led3
  1. Continual source-free active domain adaptation for nasopharyngeal carcinoma tumor segmentation across multiple hospitals.2025Neural networks : the official journal of the International Neural Network Society
  2. Research progress on mechanism and imaging of temporal lobe injury induced by radiotherapy for head and neck cancer.2022European radiology
  3. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
All its trials on ClinicalTrials.gov, any status1
  1. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
More papers found outside PubMed (not counted)5
  1. Spontaneous resolution of laryngeal contact granuloma following radiotherapy for nasopharyngeal carcinoma: A case report2025Asian Journal of Surgeryarticle
  2. Synthesis of gold nanoparticles using Ginkgo biloba leaf extract and its in vitro anticancer effects on nasopharyngeal carcinoma cells2024Alexandria Engineering Journalarticle
  3. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figsharereview
  4. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset
  5. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 5 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

3 hospitals in Changchun for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapySurgeryImaging & AI
Papers it led5
  1. FSCN1 regulates TGF-β signalling to promote esophageal squamous cell carcinoma metastasis via stabilizing THBS1 mRNA.2025Communications biologyFree full text
  2. FBXO10 inhibits ferroptosis and promotes the progression of esophageal squamous cell carcinoma by post-translational mediation of ACSL4 degradation.2025Journal of molecular histology
  3. A nomogram to predict long-term survival after resection for esophageal cancer: An observational study in northeast China.2025Surgery
  4. Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.2023Cancer biology & therapyFree full text
  5. Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit.2022Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status7
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  2. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  3. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  4. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03817567Study sitePhase 1/Phase 2Start 2018-07
  5. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  6. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  7. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)15
  1. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Researchconference-abstract
  2. Combining the Albumin-to-fibrinogen ratio and pathologic factors predicts survival in surgically treated patients with esophageal squamous cell carcinoma2024ONCOLOGIEarticle
  3. Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  4. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  5. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncologyconference-abstract
  6. Safety and feasibility of neoadjuvant immunotherapy combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma2023Research Squarepreprint
  7. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  8. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  9. Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p2022Figsharedataset
  10. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  11. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  12. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  13. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  14. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset
  15. [Retracted] MicroRNA‑338‑3p suppresses tumor growth of esophageal squamous cell carcinoma in vitro and in vivo2021Molecular Medicine Reportsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 76 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
76
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 9920212022: 141420222023: 181820232024: 262620242025: 882025

4 hospitals in Changchun for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07582419

    Age 18 years to 85 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  2. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin

  3. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  4. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  5. Recruiting
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Registry
    NCT05652920

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai

  6. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiation oncologyPathology / laboratory medicine
Papers it led76
  1. Combined treatments based on interventional therapy improve the prognosis of patients with HCC: an umbrella review of systematic reviews and meta-analyses.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Molecular Dissection of the AHR-AREG driven EGFR-ERK1/2-CyclinD1 axis in acquired lenvatinib resistance of Hepatocellular carcinoma.2025Biochemical pharmacology
  3. Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  4. Sex disparities in hepatocellular carcinoma immunotherapy: hormonal and genetic influences on treatment efficacy.2025Frontiers in immunologyFree full text
  5. The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM.2025Frontiers in immunologyFree full text
  6. Post-translational modifications in hepatocellular carcinoma: unlocking new frontiers in immunotherapy.2025Frontiers in immunologyFree full text
  7. Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  8. Integrated analysis and experimental validation reveal the prognostic and immunological features associated with coagulation in hepatocellular carcinoma.2025Scientific reportsFree full text
  9. Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis.2025The oncologistFree full text
  10. Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models.2024Acta biomaterialia
  11. Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano-Epidrug Effects on Immune Modulation and Antigenicity Restoration.2024Advanced materials (Deerfield Beach, Fla.)
  12. Trojan-Horse Strategy Targeting the Gut-Liver Axis Modulates Gut Microbiome and Reshapes Microenvironment for Orthotopic Hepatocellular Carcinoma Therapy.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  13. The Barthel Index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study.2024American journal of surgery
  14. ASO Author Reflections: α-Fetoprotein in Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): Beyond Diagnosis to Prognostication.2024Annals of surgical oncology
  15. Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis.2024Annals of surgical oncology
  16. Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: A comprehensive review.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  17. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of hepatocellular carcinoma (HCC).2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  18. miR-4461 inhibits liver cancer stem cells expansion and chemoresistance via regulating SIRT1.2024Carcinogenesis
  19. AZD1775 and anti-PD-1 antibody synergistically sensitize hepatoma to radiotherapy.2024Chinese medical journalFree full text
  20. Stratifying risk of failure to achieve textbook outcomes among patients undergoing hepatectomy for hepatocellular carcinoma: A multicenter score validation study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  21. Comparison of adjuvant treatment regimens for high-risk hepatocellular carcinoma: a Bayesian network meta analysis and systematic review.2024Frontiers in immunologyFree full text
  22. Unraveling the role of ADAMs in clinical heterogeneity and the immune microenvironment of hepatocellular carcinoma: insights from single-cell, spatial transcriptomics, and bulk RNA sequencing.2024Frontiers in immunologyFree full text
  23. Efficacy of ginseng-based Renshenguben oral solution for cancer-related fatigue among patients with advanced-stage hepatocellular carcinoma: A prospective multicenter cohort study.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  24. In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma.2024Journal of controlled release : official journal of the Controlled Release Society
  25. Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure.2024Life sciences
  26. A novel disulfidptosis-related lncRNA signature for predicting prognosis and potential targeted therapy in hepatocellular carcinoma.2024MedicineFree full text
  27. Roles of cGAS-STING Pathway in Radiotherapy Combined with Immunotherapy for Hepatocellular Carcinoma.2024Molecular cancer therapeutics
  28. Compromised macrophages contribute to progression of MASH to hepatocellular carcinoma in FGF21KO mice.2024Science advancesFree full text
  29. Ultrasound-triggered nano delivery of lenvatinib for selective immunotherapy treatment against hepatocellular carcinoma.2024Scientific reportsFree full text
  30. Renal Clearable Nanodots-Engineered Erythrocytes with Enhanced Circulation and Tumor Accumulation for Photothermal Therapy of Hepatocellular Carcinoma.2024Small (Weinheim an der Bergstrasse, Germany)
  31. Development and validation of nomograms to predict survival and recurrence after hepatectomy for intermediate/advanced (BCLC stage B/C) hepatocellular carcinoma.2024Surgery
  32. Proteomic and phosphoproteomic profiling of urinary small extracellular vesicles in hepatocellular carcinoma.2024The Analyst
  33. Prognostic significance of nodular number in patients undergoing hepatectomy of intermediate-stage hepatocellular carcinoma.2024The British journal of surgery
  34. Leveraging SEER data through machine learning to predict distant lymph node metastasis and prognosticate outcomes in hepatocellular carcinoma patients.2024The journal of gene medicine
  35. LncRNA NKILA inhibits HBV replication by repressing NF-κB signalling activation.2024Virologica SinicaFree full text
  36. Letter: Rethinking the lower incidence of HCC in HIV-infected patients- A closer look at confounding factors.2023Alimentary pharmacology & therapeutics
  37. Severe pleural effusion after hepatectomy for hepatocellular carcinoma: multicentre retrospective study.2023BJS openFree full text
  38. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular car2023BMJ openFree full text
  39. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.2023Computers in biology and medicine
  40. Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma.2023Experimental cell research
  41. Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis.2023Frontiers in immunologyFree full text
  42. Bibliometric study of immunotherapy for hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  43. Unveiling efferocytosis-related signatures through the integration of single-cell analysis and machine learning: a predictive framework for prognosis and immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  44. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  45. From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification.2023GutFree full text
  46. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?2023Hepatobiliary & pancreatic diseases international : HBPD INT
  47. Nanodelivery of scutellarin induces immunogenic cell death for treating hepatocellular carcinoma.2023International journal of pharmaceutics
  48. Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma.2023International journal of pharmaceutics
  49. Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.2023Investigational new drugs
  50. Development and validation of a model to predict the risk of distant metastases from hepatocellular carcinoma: a real-world retrospective study.2023Journal of cancer research and clinical oncologyFree full text
  51. Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses.2023Journal of hepatology
  52. Glycoproteomic Analysis of Urinary Extracellular Vesicles for Biomarkers of Hepatocellular Carcinoma.2023Molecules (Basel, Switzerland)Free full text
  53. Pseudolaric acid B triggers cell apoptosis by activating AMPK/JNK/DRP1/mitochondrial fission pathway in hepatocellular carcinoma.2023Toxicology
  54. The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis.2022Acta pharmacologica SinicaFree full text
  55. Application of a Convolutional Neural Network for Multitask Learning to Simultaneously Predict Microvascular Invasion and Vessels that Encapsulate Tumor Clusters in Hepatocellular Carcinoma.2022Annals of surgical oncologyFree full text
  56. Liver biopsy of chronic hepatitis B patients indicates HBV integration profile may complicate the endpoint and effect of entecavir treatment.2022Antiviral research
  57. Long non-coding RNA FOXP4-AS1 facilitates the biological functions of hepatocellular carcinoma cells via downregulating ZC3H12D by mediating H3K27me3 through recruitment of EZH2.2022Cell biology and toxicologyFree full text
  58. Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies.2022European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  59. Associations between Extracellular Matrix Protein 1 Gene Polymorphism and Progression of Liver Disease.2022Genetics researchFree full text
  60. Canthaxanthin shows anti-liver aging and anti-liver fibrosis effects by down-regulating inflammation and oxidative stress in vivo and in vitro.2022International immunopharmacology
  61. Polymeric nanomedicines for the treatment of hepatic diseases.2022Journal of nanobiotechnologyFree full text
  62. Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: A systematic review and meta-analysis.2022Liver international : official journal of the International Association for the Study of the Liver
  63. Bioinformatic identification of differentially expressed genes associated with hepatocellular carcinoma prognosis.2022MedicineFree full text
  64. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.2022MedicineFree full text
  65. Diagnostic performance of circulating tumor DNA as a minimally invasive biomarker for hepatocellular carcinoma: a systematic review and meta-analysis.2022PeerJFree full text
  66. Type-III interferon stimulated gene TRIM31 mutation in an HBV patient blocks its ability in promoting HBx degradation.2022Virus research
  67. The mononuclear phagocyte system in hepatocellular carcinoma.2022World journal of gastroenterologyFree full text
  68. Ataxia telangiectasia mutated inhibitor-loaded copper sulfide nanoparticles for low-temperature photothermal therapy of hepatocellular carcinoma.2021Acta biomaterialia
  69. PDLIM2 prevents the malignant phenotype of hepatocellular carcinoma cells by negatively regulating β-catenin.2021Cancer gene therapy
  70. Lysionotin induces apoptosis of hepatocellular carcinoma cells via caspase-3 mediated mitochondrial pathway.2021Chemico-biological interactions
  71. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  72. A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  73. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.2021International journal of biological sciencesFree full text
  74. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.2021Life sciences
  75. Synthesis and Anti-Hepatocarcinoma Effect of Amino Acid Derivatives of Pyxinol and Ocotillol.2021Molecules (Basel, Switzerland)Free full text
  76. XPD Polymorphisms and Risk of Hepatocellular Carcinoma and Gastric Cancer: A Meta-Analysis.2021Technology in cancer research & treatmentFree full text
Chinese-language papers (not in the count)1
  1. [Advances and controversies of statins application in prevention and treatment of hepatocellular carcinoma].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status28
  1. Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment DecisionsNot yet recruitingNCT07582419Lead sponsorStart 2026-04
  2. Standing Position Ultrasonography: Imaging Efficacy in Detecting Liver Diaphragmatic Dome Blind Area LesionsCompletedNCT07579533Lead sponsorStart 2024-02
  3. Contrast-Enhanced Ultrasound for Early Assessment of Microwave Ablation in HCCCompletedNCT07598331Lead sponsorN/AStart 2021-06
  4. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  5. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  6. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  7. Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCCRecruitingNCT05652920Study sitePhase 1/Phase 2Start 2022-12
  8. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  9. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCWithdrawnNCT05212922Study sitePhase 2Start 2023-06
  10. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  11. SynOV1.1 Intratumoral Injection StudyStatus unknownNCT04612504Study sitePhase 1Start 2022-06
  12. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Study sitePhase 2Start 2022-04
  13. Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular CarcinomaStatus unknownNCT05626985Study siteStart 2022-10
  14. Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular CarcinomaStatus unknownNCT06141109Study sitePhase 1/Phase 2Start 2022-01
  15. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Study sitePhase 2Start 2022-12
  16. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07
  17. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  18. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  19. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08
  20. Prospective Surveillance for Very Early Hepatocellular CarcinomaStatus unknownNCT03588442Study siteStart 2018-07
  21. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  22. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  23. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  24. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  25. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  26. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05
  27. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06
  28. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 41 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
41
2021–2025
Trials led
16
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 7720212022: 8820222023: 7720232024: 101020242025: 882025

4 hospitals in Changchun for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 14

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07615374

    Age not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  2. Recruiting
    The PRE-VAIL Study
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07176624

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  3. Recruiting
    Distribution Characteristics of Helicobacter Pylori
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07253948

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  4. Recruiting
    The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06881043

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  5. Recruiting
    The Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06929949

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  6. Recruiting
    Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT07119463

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  7. Not yet recruiting
    PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07031011

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  8. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  9. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  10. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  11. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  12. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  13. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  14. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsEarly detection & endoscopy
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineRadiation oncologyClinical trials / research unit
Papers it led41
  1. The Clinical Prognostic Value of Lactylation-Regulated Proteins in Gastric Cancer.2026Journal of proteome researchFree full text
  2. RGS1 can serve as a long-term prognostic marker in gastric cancer by promoting the infiltration and polarization of macrophages.2025Biochimica et biophysica acta. Molecular basis of disease
  3. Periodontal disease and gastric and colorectal cancers: mechanisms and therapeutic perspectives.2025Frontiers in cellular and infection microbiologyFree full text
  4. Recent progress in the study of exosomes in the gastric cancer immune microenvironment.2025Frontiers in immunologyFree full text
  5. Protein phosphatase 1 regulatory subunit 15 A (PPP1R15A) promoted the progression of gastric cancer by activating cell autophagy under energy stress.2025Journal of experimental & clinical cancer research : CRFree full text
  6. Gastric cancer-related mortality in the United States from 1999 to 2023.2025MedicineFree full text
  7. Roles of plasma proteins in mediating the causal effect of the lipid species on gastric cancer: Insights from proteomic and two-step Mendelian randomization.2025MedicineFree full text
  8. 5-hydroxymethylcytosines from circulating cell-free DNA as noninvasive prognostic markers for gastric cancer.2025PloS oneFree full text
  9. Integrative pan-cancer analysis and experiment validation identified GLS as a biomarker in tumor progression, prognosis, immune microenvironment, and immunotherapy.2025Scientific reportsFree full text
  10. Postoperative therapy for local-advanced gastric cancer: A systematic review and meta-analysis.2024Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  11. Exploration of signature based on T cell-related genes in stomach adenocarcinoma by analysis of single cell sequencing data.2024AgingFree full text
  12. Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients.2024BMC cancerFree full text
  13. Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.2024Biochimica et biophysica acta. Molecular basis of disease
  14. Lung enteric-type adenocarcinoma with gastric metastasis: a rare case report and literature review.2024Frontiers in immunologyFree full text
  15. Genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA as noninvasive diagnostic markers for gastric cancer.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  16. Appraising associations between signature lipidomic biomarkers and digestive system cancer risk: novel evidences from a prospective cohort study of UK Biobank and Mendelian randomization analyses.2024Lipids in health and diseaseFree full text
  17. A case of malignant gastric glomus tumor and literature review: A case report.2024MedicineFree full text
  18. Development and validation of self-screening tool for nutrition risk in patients with gastric cancer after gastrectomy: A study protocol.2024Nursing openFree full text
  19. Nine-Gene Prognostic Signature Related to Gut Microflora for Predicting the Survival in Gastric Cancer Patients.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  20. Emphasis on the clinical relationship between alpha-fetoprotein and hepatoid adenocarcinoma of the stomach: a retrospective study.2023BMC gastroenterologyFree full text
  21. TRIP 13-dependent pathways promote the development of gastric cancer.2023Functional & integrative genomicsFree full text
  22. KLF3 Transcription Activates WNT1 and Promotes the Growth and Metastasis of Gastric Cancer via Activation of the WNT/β-Catenin Signaling Pathway.2023Laboratory investigation; a journal of technical methods and pathology
  23. Predictive value of hepatitis B serological indicators for mortality among cancer survivors and validation in a gastric cancer cohort.2023PloS oneFree full text
  24. Gastric defect closure after endoscopic full-thickness resection: the closing while dissecting technique.2023Surgical endoscopy
  25. MoS2 QDs-MXene heterostructure-based ECL sensor for the detection of miRNA-135b in gastric cancer exosomes.2023Talanta
  26. Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023).2023World journal of gastroenterologyFree full text
  27. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.2022BMC cancerFree full text
  28. A glutathione-responsive sulfur dioxide polymer prodrug selectively induces ferroptosis in gastric cancer therapy.2022Biomaterials science
  29. circXRCC5 foster gastric cancer growth and metastasis by the HNRNPC/circXRCC5/miR-655-3p/RREB1/UBA2 positive feedback loop.2022Cancer gene therapy
  30. Exosome-mediated lncRNA SND1-IT1 from gastric cancer cells enhances malignant transformation of gastric mucosa cells via up-regulating SNAIL1.2022Journal of translational medicineFree full text
  31. DEK modulates both expression and alternative splicing of cancer‑related genes.2022Oncology reportsFree full text
  32. Development and verification of an immune-related gene prognostic index for gastric cancer.2022Scientific reportsFree full text
  33. Functional genomics screening identifies aspartyl-tRNA synthetase as a novel prognostic marker and a therapeutic target for gastric cancers.2022The Journal of pathology
  34. Development of cancer-associated fibroblasts subtype and prognostic model in gastric cancer and the landscape of tumor microenvironment.2022The international journal of biochemistry & cell biology
  35. Gene expression barcode values reveal a potential link between Parkinson's disease and gastric cancer.2021AgingFree full text
  36. Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.2021BMC cancerFree full text
  37. The emerging role of miR-10 family in gastric cancer.2021Cell cycle (Georgetown, Tex.)Free full text
  38. MiR-10b-5p inhibits tumorigenesis in gastric cancer xenograft mice model through down-regulating Tiam1.2021Experimental cell research
  39. Targeting miR-148b-5p Inhibits Immunity Microenvironment and Gastric Cancer Progression.2021Frontiers in immunologyFree full text
  40. Mucosal microbial microenvironment in early gastric neoplasia and non-neoplastic gastric disease.2021Journal of gastroenterology and hepatology
  41. XPD Polymorphisms and Risk of Hepatocellular Carcinoma and Gastric Cancer: A Meta-Analysis.2021Technology in cancer research & treatmentFree full text
Chinese-language papers (not in the count)1
  1. [Pylorus-preserving gastrectomy and segmental gastrectomy: discrimination of concepts and surgical procedures].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status45
  1. The PRE-VAIL StudyRecruitingNCT07176624Lead sponsorN/AStart 2025-09
  2. The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric CancerRecruitingNCT06881043Lead sponsorStart 2024-11
  3. Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer SurgeryRecruitingNCT07119463Lead sponsorPhase 2Start 2024-10
  4. The Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal GastrectomyRecruitingNCT06929949Lead sponsorStart 2024-11
  5. A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)Status unknownNCT05466019Lead sponsorPhase 2Start 2021-05
  6. The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach CancerStatus unknownNCT05000554Lead sponsorPhase 2Start 2021-07
  7. Radical Gastrectomy Within Enhanced Recovery Programs(ERAS): a Prospective Randomized Controlled TrialStatus unknownNCT03046303Lead sponsorN/AStart 2017-02
  8. Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002CompletedNCT01830907Lead sponsorEarly phase 1Start 2012-01
  9. Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric CancerRecruitingNCT07615374Lead (inferred)N/AStart 2026-05
  10. PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal CancerNot yet recruitingNCT07031011Lead (inferred)Phase 1Start 2025-06
  11. Distribution Characteristics of Helicobacter PyloriRecruitingNCT07253948Lead (inferred)Start 2025-10
  12. Microbiota and Metabolomics of Intestinal Type of Gastric CancerStatus unknownNCT06079554Lead (inferred)Start 2024-03
  13. The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric CancerCompletedNCT04694183Lead (inferred)Phase 2Start 2020-08
  14. Spleen-Preserving No. 10 Lymph Node Dissection in Gastric CancerStatus unknownNCT04050787Lead (inferred)N/AStart 2019-07
  15. Uncut Roux-en-Y vs Roux-en-YStatus unknownNCT03349398Lead (inferred)N/AStart 2017-11
  16. The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction After Laparoscopy-assisted Distal Gastrectomy for GastricStatus unknownNCT02694081Lead (inferred)Phase 2Start 2016-02
  17. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  18. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  19. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  20. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  21. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Study sitePhase 1/Phase 2Start 2024-06
  22. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  23. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap MethodRecruitingNCT05450835Study siteN/AStart 2022-09
  24. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  25. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  26. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  27. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Study sitePhase 3Start 2021-05
  28. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  29. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal MetastasisStatus unknownNCT04222114Study sitePhase 3Start 2020-10
  30. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  31. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  32. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  33. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  34. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT04053205Study sitePhase 1/Phase 2Start 2019-11
  35. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  36. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  37. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  38. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  39. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  40. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  41. Study of Metatinib Tromethamine TabletStatus unknownNCT02650375Study sitePhase 1Start 2015-10
  42. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  43. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  44. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  45. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Changchun for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Incidence trends and a nomogram for predicting overall survival in children with hepatoblastoma: A population-based analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Earlier papers (2016–2020)3
  1. Novel treatment of refractory / recurrent pulmonary hepatoblastoma.2020Pediatrics international : official journal of the Japan Pediatric Society
  2. Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma.2019Bioscience reports
  3. Kockdown of OIP5-AS1 expression inhibits proliferation, metastasis and EMT progress in hepatoblastoma cells through up-regulating miR-186a-5p and down-regulating ZEB1.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 3 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Changchun for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changchun for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Primary maxillofacial chordoma: a rare case report and literature review.2019The Journal of international medical research

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 17 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
17
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 8820222023: 1120232024: 2220242025: 002025

10 hospitals in Changchun for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led17
  1. Multifunctional poly(amino acid) nanomedicine modulates macrophage polarization for osteosarcoma immunotherapy.2026Journal of controlled release : official journal of the Controlled Release Society
  2. Biomaterials-Boosted Immunotherapy for Osteosarcoma.2024Advanced healthcare materials
  3. The role of neutrophils in osteosarcoma: insights from laboratory to clinic.2024Frontiers in immunology
  4. Single-cell RNA datasets and bulk RNA datasets analysis demonstrated C1Q+ tumor-associated macrophage as a major and antitumor immune cell population in osteosarcoma.2023Frontiers in immunology
  5. Effective natural inhibitors targeting IGF-1R by computational study.2022Aging
  6. MiR-659-3p inhibits osteosarcoma progression and metastasis by inhibiting cell proliferation and invasion via targeting SRPK1.2022BMC cancer
  7. SRPK1 promotes cell proliferation and tumor growth of osteosarcoma through activation of the NF-κB signaling pathway.2022Biological chemistry
  8. Colorimetric identification of miRNA-195 sequence for diagnosing osteosarcoma.2022Biotechnology and applied biochemistry
  9. Identification of PSMD14 as a potential novel prognosis biomarker and therapeutic target for osteosarcoma.2022Cancer reports (Hoboken, N.J.)
  10. Deduction of CDC42EP3 suppress development and progression of osteosarcoma.2022Experimental cell research
  11. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.2022Frontiers in immunology
  12. Role of extracellular vesicles in osteosarcoma.2022International journal of medical sciences
  13. Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma.2021Aging
  14. Circular RNA circPVT1 Contributes to Doxorubicin (DXR) Resistance of Osteosarcoma Cells by Regulating TRIAP1 via miR-137.2021BioMed research international
  15. Breast osteosarcoma originating from a malignant phyllodes tumor: A case report of a rare neoplasm.2021Medicine
  16. Ginsenoside Rg5 Inhibits Human Osteosarcoma Cell Proliferation and Induces Cell Apoptosis through PI3K/Akt/mTORC1-Related LC3 Autophagy Pathway.2021Oxidative medicine and cellular longevity
  17. The roles of metastasis-related proteins in the development of giant cell tumor of bone, osteosarcoma and Ewing's sarcoma.2021Technology and health care : official journal of the European Society for Engineering and Medicine
Chinese-language papers (not in the count)1
  1. [Bioinformatics-based identification of key genes CDC5L and related pathways in osteosarcoma and Ewing's sarcoma].2022Zhongguo gu shang = China journal of orthopaedics and traumatology
Earlier papers (2016–2020)18
  1. LncRNA DLEU2 promotes tumour growth by sponging miR-337-3p in human osteosarcoma.2020Cell biochemistry and function
  2. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.2020Drug delivery
  3. Long noncoding RNA PVT1 promotes metastasis via miR-484 sponging in osteosarcoma cells.2020European review for medical and pharmacological sciences
  4. Circular RNA PVT1 promotes metastasis via regulating of miR-526b/FOXC2 signals in OS cells.2020Journal of cellular and molecular medicine
  5. A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma.2020Scientific reports
  6. Primary Pediatric Renal Primitive Neuroectodermal Tumor: A Case Report With Different Stage CT and MRI Images.2020Urology
  7. LncRNA HIF2PUT inhibited osteosarcoma stem cells proliferation, migration and invasion by regulating HIF2 expression.2019Artificial cells, nanomedicine, and biotechnology
  8. Interleukin-35 suppresses antitumor activity of circulating CD8+ T cells in osteosarcoma patients.2019Connective tissue research
  9. In Vitro Generation of Anti-Osteosarcoma Cytotoxic Activity Using Dendritic Cells Loaded with Heat Shock Protein 70-Peptide Complexes.2019Fetal and pediatric pathology
  10. The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment.2018Colloids and surfaces. B, Biointerfaces
  11. miR‑15a represses cancer cell migration and invasion under conditions of hypoxia by targeting and downregulating Bcl‑2 expression in human osteosarcoma cells.2018International journal of oncology
  12. lncRNA LINC01296 regulates the proliferation, metastasis and cell cycle of osteosarcoma through cyclin D1.2018Oncology reports
  13. MicroRNA-152 Suppresses Human Osteosarcoma Cell Proliferation and Invasion by Targeting E2F Transcription Factor 3.2018Oncology research
  14. Rare adrenal gland incidentaloma: an unusual Ewing's sarcoma family of tumor presentation and literature review.2017BMC urology
  15. Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: a meta-analysis.2017European journal of cancer care
  16. [Ewing's sarcoma misdiagnosed as nonossifying fibroma: a case report].2017Zhongguo gu shang = China journal of orthopaedics and traumatology
  17. A polysaccharide from the leaves of Aralia elata induces apoptosis in U-2 OS cells via mitochondrial-dependent pathway.2016International journal of biological macromolecules
  18. Shock wave-induced ATP release from osteosarcoma U2OS cells promotes cellular uptake and cytotoxicity of methotrexate.2016Journal of experimental & clinical cancer research : CR

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Changchun for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 7 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 3320232024: 0020242025: 002025

3 hospitals in Changchun for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurosurgeryNeurologySurgery (general/hepatobiliary/pancreatic)

Over half of these papers are lab or animal studies.

Papers it led7
  1. Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN.2023Cell death & disease
  2. Oxidative stress as a key event in 2,6-dichloro-1,4-benzoquinone-induced neurodevelopmental toxicity.2023Ecotoxicology and environmental safety
  3. Maltol inhibits oxygen glucose deprivation‑induced chromatinolysis in SH‑SY5Y cells by maintaining pyruvate level.2023Molecular medicine reports
  4. Different tumorigenicity and distinct metastasis and gene signature between orthotopic and subcutaneous neuroblastoma xenografted mice.2022Aging
  5. DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family.2022Brain : a journal of neurology
  6. Low-viscosity sodium alginate combined with TiO2 nanoparticles for improving neuroblastoma treatment.2021International journal of biological macromolecules
  7. Undifferentiated embryonal sarcoma of the liver with epithelioid features in an adult patient: A case report.2021Medicine
Earlier papers (2016–2020)12
  1. A five-gene signature derived from m6A regulators to improve prognosis prediction of neuroblastoma.2020Cancer biomarkers : section A of Disease markers
  2. Role and toxicity of radiation therapy in neuroblastoma patients: A literature review.2020Critical reviews in oncology/hematology
  3. An elongated tract of polyQ in the carboxyl‑terminus of human α1A calcium channel induces cell apoptosis by nuclear translocation.2020Oncology reports
  4. Silencing CASC11 curbs neonatal neuroblastoma progression through modulating microRNA-676-3p/nucleolar protein 4 like (NOL4L) axis.2020Pediatric research
  5. RNA N6-methyladenosine modification is required for miR-98/MYCN axis-mediated inhibition of neuroblastoma progression.2020Scientific reports
  6. CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma cells against Aβ25-35-induced neurotoxicity by inhibiting the pCRMP2/NMDAR2B signaling pathway.2019Chemico-biological interactions
  7. Treatment of Neuroblastoma with a Novel Delayed Intensification Chemotherapy.2019Indian journal of pediatrics
  8. Endoplasmic reticulum stress regulates oxygen-glucose deprivation-induced parthanatos in human SH-SY5Y cells via improvement of intracellular ROS.2018CNS neuroscience & therapeutics
  9. Trehalose inhibits H2O2-induced autophagic death in dopaminergic SH-SY5Y cells via mitigation of ROS-dependent endoplasmic reticulum stress and AMPK activation.2018International journal of medical sciences
  10. miR-205 Inhibits Neuroblastoma Growth by Targeting cAMP-Responsive Element-Binding Protein 1.2018Oncology research
  11. Lycopene protects human SH‑SY5Y neuroblastoma cells against hydrogen peroxide‑induced death via inhibition of oxidative stress and mitochondria‑associated apoptotic pathways.2016Molecular medicine reports
  12. Stimulus-dependent neuronal cell responses in SH-SY5Y neuroblastoma cells.2016Molecular medicine reports

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Changchun for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 17 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.0%.

Papers led
17
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 6620232024: 3320242025: 222025

3 hospitals in Changchun for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07509086

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  2. Recruiting
    Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
    Phase
    Not given
    Started
    2023-06
    Registry
    NCT06252792

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  3. Recruiting
    Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
    Phase
    Not given
    Started
    2021-09
    Registry
    NCT06099912

    Age 65 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  4. Not yet recruiting
    Risk-adapted Therapeutic Strategy in +1q NDMM
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07045168

    Age not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  5. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  6. Recruiting
    68Ga-BCMA PET/CT in Multiple Myeloma
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Registry
    NCT07319897

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Changchun, Shijiazhuang

  7. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  8. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  9. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  10. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  11. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceDrug combinations
Departments in papersRadiology / nuclear medicineMedical oncologyNeurosurgery
Papers it led17
  1. Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.2025Blood reviews
  2. Development and validation of a prognostic staging system for primary plasma cell leukemia.2025Journal of hematology & oncologyFree full text
  3. Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis.2024Clinical medicine (London, England)Free full text
  4. Palmitic acid inhibits macrophage-mediated chemotherapy resistance in multiple myeloma via ALOX12 signaling.2024International immunopharmacology
  5. Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.2024Journal of hematology & oncologyFree full text
  6. Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma.2023American journal of hematology
  7. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.2023American journal of hematology
  8. More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.2023Annals of hematology
  9. Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.2023Annals of hematologyFree full text
  10. Diagnostic value of WB-DWI versus 18F-FDG PET/CT for the detection of multiple myeloma.2023Indian journal of cancer
  11. Interleukin-10 increases macrophage-mediated chemotherapy resistance via FABP5 signaling in multiple myeloma.2023International immunopharmacology
  12. The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma.2022Blood cancer journalFree full text
  13. Decoding DNA methylation in epigenetics of multiple myeloma.2022Blood reviews
  14. Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma.2022Medical oncology (Northwood, London, England)Free full text
  15. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.2021Asia-Pacific journal of clinical oncology
  16. Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma.2021BMC medical imagingFree full text
  17. Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma.2021MedicineFree full text
Chinese-language papers (not in the count)1
  1. [A predictive model based on risk factors for early mortality in patients with newly diagnosed multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status27
  1. IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell LeukemiaRecruitingNCT07509086Lead sponsorPhase 2Start 2025-12
  2. Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple MyelomaStatus unknownNCT04063189Lead sponsorPhase 2Start 2017-03
  3. Risk-adapted Therapeutic Strategy in +1q NDMMNot yet recruitingNCT07045168Lead (inferred)Start 2025-09
  4. Dara-PD in the Treatment of Patients With First Relapse of Multiple MyelomaRecruitingNCT06252792Lead (inferred)Start 2023-06
  5. Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMMRecruitingNCT06099912Lead (inferred)Start 2021-09
  6. A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial TreatmentStatus unknownNCT06109233Lead (inferred)Start 2022-01
  7. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  8. 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Study sitePhase 2/Phase 3Start 2025-12
  9. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  10. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  11. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  12. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  13. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  14. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  15. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  16. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  17. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  18. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  19. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  20. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  21. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  22. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  23. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  24. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  25. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  26. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  27. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

1 hospital in Changchun for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

  2. Not yet recruiting
    SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2026-09
    Registry
    NCT07830238

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
  1. SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07830238Study siteEarly phase 1Start 2026-09
  2. Study of YK012 in B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06580301Study sitePhase 1/Phase 2Start 2024-09
  3. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Changchun for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunosuppressive treatmentThrombopoietin drugs
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 4 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.0%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025

1 hospital in Changchun for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEBV & infection triggersChildrenDiagnosis & prognosis
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changchun for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Treatment of hemophilic arthropathy of ankle by arthrodesis with a small anterior approach:a case report].2023Zhongguo gu shang = China journal of orthopaedics and traumatology
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 2 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 7.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Changchun for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Changchun for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 11 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 2.3%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 4420232024: 1120242025: 112025

2 hospitals in Changchun for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07699770

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisAcute attack treatmentImaging
Departments in papersNeurology
Papers it led11
  1. Differences in clinical phenotype, laboratory, and imaging manifestations between AQP4 IgG positive and AQP4 MOG IgG double negative NMOSD: How to correctly diagnose the two.2025Autoimmunity reviews
  2. Effects of intravenous pulse methylprednisolone in neuromyelitis optica during the acute phase.2024Annals of clinical and translational neurologyFree full text
  3. Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?2023Clinical and experimental immunology
  4. Causal relationships between susceptibility and severity of COVID-19 and neuromyelitis optica spectrum disorder (NMOSD) in European population: a bidirectional Mendelian randomized study.2023Frontiers in immunologyFree full text
  5. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.2023Multiple sclerosis and related disorders
  6. Oily fish and raw vegetable consumption can decrease the risk of AQP4-positive neuromyelitis optica spectrum disorders: a Mendelian-randomization study.2023Scientific reportsFree full text
  7. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges.2022Autoimmunity reviews
  8. Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD.2022CNS neuroscience & therapeuticsFree full text
  9. Thrombotic thrombocytopenic purpura with neurological impairment: A Review.2022MedicineFree full text
  10. AQP4-IgG positive paraneoplastic NMOSD: A case report and review.2021Brain and behaviorFree full text
  11. Clinical characteristics of MOG antibody disease: two case reports.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory TrialNot yet recruitingNCT07699770Study sitePhase 4Start 2026-06
More papers found outside PubMed (not counted)2
  1. A single-electrode system for ZIF-67 enhanced luminol electrochemiluminescence detection of AQP4 antibody2025Sensors and Actuators B Chemicalarticle
  2. Metal-organic frameworks-based coreactants for enhanced electrochemiluminescence detection of AQP4 antibodies2025Electrochimica Actaarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Changchun for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

  2. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  3. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an

  4. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

  5. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Erythroderma combined with deeper dermal dermatophytosis due to Trichophyton rubrum in a patient with myasthenia gravis: first case report and literature review.2023BMC infectious diseasesFree full text
All its trials on ClinicalTrials.gov, any status10
  1. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Study sitePhase 1Start 2025-09
  2. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  3. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  4. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  5. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  6. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  7. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03
  8. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10
  9. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingNCT05070858Study sitePhase 3Start 2021-12
  10. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Study sitePhase 2Start 2020-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 4 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 002025

2 hospitals in Changchun for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenImaging & blood flowRevascularisation surgery
Departments in papersNeurosurgeryPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 2 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

1 hospital in Changchun for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Treatment (chelation, zinc)Diagnosis & copper tests
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 5 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.9%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

1 hospital in Changchun for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

3 hospitals in Changchun for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologyClinical trials / research unit
Papers it led2
  1. Exploring the causal relationship between Takayasu arteritis and inflammatory bowel disease using Mendelian randomization.2024Immunologic research
  2. AMPK hyperactivity maintains the survival of vasculogenic T cells in patients with Takayasu's arteritis.2023Clinical and experimental rheumatology
Earlier papers (2016–2020)1
  1. Ultrasound diagnosis and follow-up of Takayasu arteritis with femoral vein involvement.2019Journal of vascular surgery. Venous and lymphatic disorders
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Changchun for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

3 hospitals in Changchun for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changchun for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Changchun for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changchun for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 3 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 1.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Changchun for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology
Papers it led3
  1. Recurrent aortic-arch pseudoaneurysm eroding into the left main bronchus following descending thoracic aortic stent repair.2023Journal of cardiothoracic surgery
  2. Long-segment diffuse cervical spinal cord involvement as the first episode of neuro-Behçet's disease: a case report.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  3. Association between IL1B -511C/T polymorphism and Behçet's disease: a meta-analysis.2021The Journal of international medical research
Earlier papers (2016–2020)1
  1. Serum PLR and LMR in Behçet's disease: Can they show the disease activity?2017Medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Changchun for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.

Papers led
7
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 0020232024: 1120242025: 112025

6 hospitals in Changchun for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Nefecon and Ambrisentan in IgA Nephropathy
    Phase
    Phase 4
    Started
    2025-09
    Registry
    NCT07030894

    Age 18 years to 70 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led7
  1. Inflammatory and nutritional indexes as predictors of acute kidney injury in patients with Immunoglobulin A nephropathy: a retrospective study.2025PeerJ
  2. Cathepsin S (CTSS) in IgA nephropathy: an exploratory study on its role as a potential diagnostic biomarker and therapeutic target.2024Frontiers in immunology
  3. Great prognosis of concurrent anti-GBM disease and IgA nephropathy in a young woman: A case report.2022Medicine
  4. Renal amyloidogenic leukocyte chemotactic factor 2 combined with IgA nephropathy: A case report.2022Medicine
  5. A noninvasive artificial neural network model to predict IgA nephropathy risk in Chinese population.2022Scientific reports
  6. Increased Tim-3+ monocytes/macrophages are associated with disease severity in patients with IgA nephropathy.2021International immunopharmacology
  7. Paraneoplastic immunoglobulin A nephropathy in a patient with lung adenocarcinoma: A case report and literature review.2021The Journal of international medical research
Earlier papers (2016–2020)6
  1. Increased Non-switched Memory B Cells are Associated with Plasmablasts, Serum IL-6 Levels and Renal Functional Impairments in IgAN Patients.2020Immunological investigations
  2. Identification of key genes, pathways and potential therapeutic agents for IgA nephropathy using an integrated bioinformatics analysis.2020Journal of the renin-angiotensin-aldosterone system : JRAAS
  3. Increased frequency of PD-1hiCXCR5- T cells and B cells in patients with newly diagnosed IgA nephropathy.2020Scientific reports
  4. Clinicopathologic correlations of renal biopsy findings from northeast China: A 10-year retrospective study.2019Medicine
  5. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.2017BMC nephrology
  6. Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy.2016Journal of immunology research
All its trials on ClinicalTrials.gov, any status3
  1. Nefecon and Ambrisentan in IgA NephropathyRecruitingNCT07030894Lead sponsorPhase 4Start 2025-09
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Changchun for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report.2022Endocrine, metabolic & immune disorders drug targets
Earlier papers (2016–2020)1
  1. [A case report of eight-year follow-up after splenectomy for Gaucher disease].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changchun for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaActive, not recruitingNCT05972551Study sitePhase 3Start 2024-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 11 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 3.7%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 6620232024: 0020242025: 002025

4 hospitals in Changchun for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led11
  1. The Albumin-Bilirubin Score as a Predictor of Liver-Related Mortality in Primary Biliary Cholangitis with Compensated Cirrhosis.2023Digestive diseases (Basel, Switzerland)
  2. Soluble immune checkpoints are elevated in patients with primary biliary cholangitis.2023European journal of medical research
  3. TR score: A noninvasive model to predict histological stages in patients with primary biliary cholangitis.2023Frontiers in immunology
  4. A large-scale plasma proteome Mendelian randomization study identifies novel causal plasma proteins related to primary biliary cholangitis.2023Frontiers in immunology
  5. The causal effects of inflammatory bowel disease on primary biliary cholangitis: A bidirectional two-sample Mendelian randomization study.2023Liver international : official journal of the International Association for the Study of the Liver
  6. FcγRIIB expression increases during primary biliary cholangitis.2023Molecular immunology
  7. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  8. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.2022Frontiers in immunology
  9. Serum metabolic profiling of targeted bile acids reveals potentially novel biomarkers for primary biliary cholangitis and autoimmune hepatitis.2022World journal of gastroenterology
  10. Expanded circulating peripheral helper T cells in primary biliary cholangitis: Tph cells in PBC.2021Molecular immunology
  11. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome in a patient with paroxysmal nocturnal hemoglobinuria: a case report.2021The Journal of international medical research
Earlier papers (2016–2020)11
  1. Serotonin: A Potent Immune Cell Modulator in Autoimmune Diseases.2020Frontiers in immunology
  2. Total bile acid to platelet ratio: A noninvasive index for predicting liver fibrosis in primary biliary cholangitis.2020MedicineRCT
  3. Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.2020PloS one
  4. The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis.2019Medical science monitor : international medical journal of experimental and clinical research
  5. Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients.2018European journal of gastroenterology & hepatology
  6. Primary biliary cirrhosis with refractory hypokalemia: A case report.2018Medicine
  7. Median arcuate ligament syndrome and arterial anastomotic bleeding inducing hepatic artery thrombosis after liver transplantation: A case report.2018Medicine
  8. Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome: A case report.2018Medicine
  9. Platelet count to spleen thickness ratio is related to histologic severity of primary biliary cholangitis.2018Medicine
  10. Red blood cell distribution width and globulin, noninvasive indicators of fibrosis and inflammation in chronic hepatitis patients.2016European journal of gastroenterology & hepatology
  11. [Association between chronic urinary tract infection and primary biliary cirrhosis].2016Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
All its trials on ClinicalTrials.gov, any status7
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  3. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08
  4. Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)Status unknownNCT04956328Study sitePhase 3Start 2021-07
  5. Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary CirrhosisCompletedNCT06715319Study sitePhase 3Start 2021-10
  6. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisActive, not recruitingNCT05050136Study sitePhase 2Start 2021-09
  7. A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)Status unknownNCT04278820Study sitePhase 2Start 2020-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Changchun for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Changchun for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Chinese-language papers (not in the count)1
  1. [Advance in genetics research on Gastrointestinal polyposis syndromes].2025Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

吉林大学第一医院

First Hospital of Jilin University

长春

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
First Bethune Hospital of Jilin University; First Bethune Hospital; Jilin University First Hospital; Cancer Center of the First Hospital of Jilin University; First Hospital of Jilin University Cancer Center; Orthopedics Center The First Hospital of Jilin University; First Hospital of jilin University; General Surgery Center of the First Hospital of Jilin University

Suggest a correctionDownload the data